Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBT (2022 - 2025)

Historic EBT for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to -$54.7 million.

  • Centessa Pharmaceuticals' EBT fell 3042.8% to -$54.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$239.3 million, marking a year-over-year decrease of 5114.73%. This contributed to the annual value of -$232.9 million for FY2024, which is 3223.1% down from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported EBT of -$54.7 million as of Q3 2025, which was down 3042.8% from -$49.6 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' EBT's 5-year high stood at -$24.7 million during Q1 2025, with a 5-year trough of -$110.3 million in Q4 2024.
  • For the 4-year period, Centessa Pharmaceuticals' EBT averaged around -$50.3 million, with its median value being -$48.9 million (2023).
  • In the last 5 years, Centessa Pharmaceuticals' EBT tumbled by 20896.53% in 2024 and then skyrocketed by 3414.61% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' EBT (Quarter) stood at -$43.8 million in 2022, then increased by 18.58% to -$35.7 million in 2023, then plummeted by 208.97% to -$110.3 million in 2024, then surged by 50.38% to -$54.7 million in 2025.
  • Its EBT stands at -$54.7 million for Q3 2025, versus -$49.6 million for Q2 2025 and -$24.7 million for Q1 2025.